Search all medical codes

MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis

CPT4 code

Name of the Procedure:

Full Sequence Analysis of the MSH2 Gene Common Name(s): MSH2 Gene Testing, Lynch Syndrome Testing Technical Term(s): MutS Homolog 2 Full Sequence Analysis, Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Gene Analysis

Summary

In this procedure, the entire DNA sequence of the MSH2 gene is analyzed to check for mutations. These mutations can indicate a predisposition to hereditary non-polyposis colorectal cancer, also known as Lynch syndrome, which is a type of colon cancer that occurs due to inherited genetic mutations.

Purpose

Medical Condition/Problem Addressed: The test identifies genetic mutations that increase the risk of developing Lynch syndrome and associated cancers (e.g., colorectal, endometrial, ovarian cancers).

Goals/Expected Outcomes: The primary goal is to detect mutations in the MSH2 gene. Early identification helps in managing and monitoring the patient's health to prevent or detect cancer early.

Indications

Specific Symptoms/Conditions:

  • Family history of Lynch syndrome-related cancers
  • Multiple cases of colorectal cancer in the family
  • Early-onset colorectal cancer

Patient Criteria: Individuals with a strong family history of Lynch syndrome, or those who have had other cancers associated with the syndrome.

Preparation

Pre-procedure Instructions:

  • No fasting or dietary restrictions required.
  • Inform the healthcare provider of any medications or supplements.

    Diagnostic Tests/Assessments:

  • Genetic counseling is often recommended before the test.
  • Collection of a detailed family history.

Procedure Description

  1. Sample Collection: A blood sample is typically drawn from the patient. Sometimes, a saliva or tissue sample may be used.
  2. DNA Extraction: The DNA is extracted from the sample in a laboratory.
  3. Sequencing: The MSH2 gene is sequenced using specialized equipment to identify any mutations.
  4. Analysis: The sequencing data is analyzed to detect any changes or mutations in the gene.

Tools/Equipment: Blood draw equipment, DNA extraction kits, sequencing machines.

Anesthesia/Sedation: Not required for the sample collection.

Duration

The sample collection takes a few minutes, but the entire process from sample collection to results can take several weeks.

Setting

Typically performed in an outpatient clinic, hospital laboratory, or specialized genetic testing facility.

Personnel

  • Phlebotomist or nurse (for sample collection)
  • Geneticist or laboratory technician (for DNA extraction and sequencing)
  • Genetic counselor (for pre- and post-test counseling)

Risks and Complications

Common:

  • Minor discomfort or bruising at the blood draw site.

    Rare:

  • Infection at the blood draw site.

    Complications: Generally very low risk.

Benefits

  • Identifies risk for Lynch syndrome and related cancers.
  • Provides information for proactive health management and surveillance.

Recovery

  • No recovery time needed for the test itself.
  • Follow-up appointments may be scheduled to discuss results and implications.

Alternatives

  • Single-site mutation testing if a specific mutation is already known in the family.
  • Multi-gene panel testing for hereditary cancer syndromes.

Pros and Cons of Alternatives:

  • Multi-gene panel testing may provide broader information but can be more expensive and complex.
  • Single-site testing is quicker but less comprehensive.

Patient Experience

During the Procedure:

  • Minimal discomfort during the blood draw.

After the Procedure:

  • Normal activities can be resumed immediately.
  • Patients may feel anxious while awaiting results; genetic counseling can provide support.

Pain Management/Comfort Measures:

  • Standard pain and comfort measures for blood draws, such as local ice packs or bandages, can be applied if needed.

Medical Policies and Guidelines for MSH2 (mutS homolog 2, colon cancer, nonpolyposis type 1) (eg, hereditary non-polyposis colorectal cancer, Lynch syndrome) gene analysis; full sequence analysis

Related policies from health plans

Similar Codes